Trefoil Factor-3 Is a Hypoxia-Triggered Pro-Tumorigenic Factor in Hepatoblastoma
Por:
Martínez-Pérez, LA, Latasa, MU, Uriarte, I, López-Pascual, A, Elurbide, J, Strnad, P, Frankova, S, Sticova, E, Fabian, O, Arechederra, M, Santamaria, E, Argemi, J, Sangro, B, Foglia, B, Parola, M, Gutiérrez-Angulo, M, Cairo, S, Bataller, R, Sancho-Bru, P, Martinez-Chantar, ML, Marin, JJG, Castaneda, A, Armengol, C, Berasain, C, Fernandez-Barrena, MG and Avila, MA
Publicada:
13 mar 2026
Resumen:
Background & Aims Hepatoblastoma (HB) is the most common malignant liver tumour in children. Despite improved survival in low-risk disease, outcomes for advanced or relapsed HB remain poor, emphasising the need for new therapeutic targets. Hypoxia, a hallmark of aggressive tumours, has recently been implicated in HB pathogenesis, but the molecular mechanisms involved are unclear. This study aimed to characterise the hypoxia-driven transcriptomic landscape of HB and identify key mediators of tumour progression.Methods Transcriptomic analyses of HB cell lines cultured under normoxic and hypoxic conditions were combined with bioinformatic interrogation of public HB datasets, immunohistochemistry of human and murine tumours and plasma ELISA assays. Functional roles of trefoil factor 3 (TFF3) were evaluated through overexpression and shRNA-mediated knockdown in vitro and in a beta-catenin/YAP-driven mouse model of HB.Results Hypoxia induced broad transcriptional reprogramming in HB cells, including significant upregulation of TFF3, a secreted oncogenic peptide. TFF3 expression was elevated in HB tissues and plasma, and colocalized with hypoxia marker carbonic anhydrase 9 (CA9). TFF3 promoted proliferation, anchorage-independent growth and cisplatin resistance under both normoxia and hypoxia. Knockdown of murine Tff3 suppressed tumour formation and angiogenesis in vivo. Transcriptomic and molecular analyses revealed that TFF3 sustains C-MYC expression and modulates mTOR/GSK3 beta signalling.Conclusions TFF3 is a hypoxia-inducible factor that enhances HB cell proliferation, survival and chemoresistance. Its tumour-promoting activity through C-MYC and mTOR pathways identifies TFF3 as a potential therapeutic target and circulating biomarker in hepatoblastoma.
Filiaciones:
Martínez-Pérez, LA:
Univ Guadalajara, Ctr Univ Altos, Dept Ciencias Salud, Tepatitlan, Mexico
Univ Navarra, Solid Tumors Program, Hepatol Lab, CIMA,CCUN, Pamplona, Spain
Latasa, MU:
Univ Navarra, Solid Tumors Program, Hepatol Lab, CIMA,CCUN, Pamplona, Spain
Inst Invest Sanit Navarra IdiSNA, Pamplona, Spain
Uriarte, I:
Univ Navarra, Solid Tumors Program, Hepatol Lab, CIMA,CCUN, Pamplona, Spain
CIBEREHD, Madrid, Spain
López-Pascual, A:
Univ Navarra, Solid Tumors Program, Hepatol Lab, CIMA,CCUN, Pamplona, Spain
Inst Invest Sanit Navarra IdiSNA, Pamplona, Spain
Elurbide, J:
Univ Navarra, Solid Tumors Program, Hepatol Lab, CIMA,CCUN, Pamplona, Spain
CIBEREHD, Madrid, Spain
Strnad, P:
Univ Hosp RWTH Aachen, Med Clin 3, Gastroenterol Metab Dis & Intens Care, Aachen, Germany
Frankova, S:
Inst Clin & Expt Med, Dept Hepatogastroenterol, Prague, Czech Republic
Sticova, E:
Inst Clin & Expt Med, Dept Hepatogastroenterol, Prague, Czech Republic
Charles Univ Prague, Hosp Kralovske Vinohrady, Fac Med 3, Dept Pathol, Prague, Czech Republic
Fabian, O:
Inst Clin & Expt Med, Dept Hepatogastroenterol, Prague, Czech Republic
Charles Univ Prague, Thomayer Univ, Fac Med 3, Dept Pathol & Mol Med, Prague, Czech Republic
Arechederra, M:
Univ Navarra, Solid Tumors Program, Hepatol Lab, CIMA,CCUN, Pamplona, Spain
Inst Invest Sanit Navarra IdiSNA, Pamplona, Spain
CIBEREHD, Madrid, Spain
Santamaria, E:
CIBEREHD, Madrid, Spain
Univ Navarra, RNA Biol & Therapeut Program, CIMA, CCUN, Pamplona, Spain
Argemi, J:
Inst Invest Sanit Navarra IdiSNA, Pamplona, Spain
CIBEREHD, Madrid, Spain
Univ Navarra, RNA Biol & Therapeut Program, CIMA, CCUN, Pamplona, Spain
Sangro, B:
Inst Invest Sanit Navarra IdiSNA, Pamplona, Spain
CIBEREHD, Madrid, Spain
Univ Navarra Clin, Liver Unit, CCUN, Pamplona, Spain
Foglia, B:
Univ Torino, Dept Clin & Biol Sci, Unit Expt Med & Clin Pathol, Turin, Italy
Parola, M:
Univ Torino, Dept Clin & Biol Sci, Unit Expt Med & Clin Pathol, Turin, Italy
Gutiérrez-Angulo, M:
Univ Guadalajara, Ctr Univ Altos, Dept Ciencias Salud, Tepatitlan, Mexico
Cairo, S:
Champ Oncol, Rockville, MD USA
Bataller, R:
CIBEREHD, Madrid, Spain
Hosp Clin Barcelona, Inst Invest Biomed August Pi & Sunyer IDIBAPS, Barcelona, Spain
Sancho-Bru, P:
CIBEREHD, Madrid, Spain
Hosp Clin Barcelona, Inst Invest Biomed August Pi & Sunyer IDIBAPS, Barcelona, Spain
Martinez-Chantar, ML:
CIBEREHD, Madrid, Spain
Basque Res & Technol Alliance, Ctr Cooperat Res Biosci CICbioGUNE, Liver Dis Lab, Bizkaia Sci & Technol Pk, Derio, Spain
Marin, JJG:
CIBEREHD, Madrid, Spain
Univ Salamanca, Expt Hepatol & Drug Targeting HEVEPHARM, IBSAL, Salamanca, Spain
:
Germans Trias & Pujol Res Inst IGTP, Childhood Liver Oncol Grp, Badalona, Spain
:
CIBEREHD, Madrid, Spain
Germans Trias & Pujol Res Inst IGTP, Childhood Liver Oncol Grp, Badalona, Spain
Berasain, C:
Univ Navarra, Solid Tumors Program, Hepatol Lab, CIMA,CCUN, Pamplona, Spain
CIBEREHD, Madrid, Spain
Fernandez-Barrena, MG:
Univ Navarra, Solid Tumors Program, Hepatol Lab, CIMA,CCUN, Pamplona, Spain
Inst Invest Sanit Navarra IdiSNA, Pamplona, Spain
CIBEREHD, Madrid, Spain
Avila, MA:
Univ Navarra, Solid Tumors Program, Hepatol Lab, CIMA,CCUN, Pamplona, Spain
Inst Invest Sanit Navarra IdiSNA, Pamplona, Spain
CIBEREHD, Madrid, Spain
Green Submitted, hybrid
|